Andy Morley

Andy Morley is an accomplished scientific leader with extensive experience in medicinal chemistry and drug discovery. Currently serving as Chief Scientific Officer at both o2h ventures and o2h group since January 2014, as well as at Opal Oncology Limited since June 2012, Andy plays a pivotal role in project management and the development of innovative cancer therapies. Previously, Andy held significant positions in prestigious organizations such as AstraZeneca, Aventis, and Rhone-Poulenc Rorer, where responsibilities included leading medicinal chemistry teams and managing research initiatives. Andy also operated as an independent consultant from 2011 to 2013, focusing on novel 3D fragment development. Andy's academic credentials include a PhD from The University of Salford and a postdoctoral fellowship at Nagoya University.